Hello kid2. I had been following the long term MSTX stats and varied studies, which are presented very well, and I understand the aspects of this disease, as well as the application of this product to other conditions in which blood flow is impaired, pointing to other potential uses for the future. The earlier studies express the same mechanisms of the product, and its helpful if one understands exactly what occurred previously, such that the studies are now modified/ more assuredly validating. One can phone the company to learn about what I call the meat and potatoes of this in its entirety, thereby getting a feel for the constancy of momentum over time, and the willingness for MSTX to reach defined objectives by adaptation. And that call possibly will further validate for the caller that these people are not in preliminary stages by any means. In fact I would say they're smokin' as in fast forward.
But I got that feel a long time ago. The movement "on track" is simply because of all of the above, over time. Now I hear and read (from the company) higher levels in success and evaluative sophistication, moving in the same direction, which for me is the "gravy" because the underpinnings are so sound. Its the result of my own interest in the extraordinary suffering that defines sickle cell disease. So, yes I do believe one can learn more and more from ongoing reports, as these trials progress. And yes, its one persons opinion (mine) that these results continue to be consistent with the greater picture, all herein IMO. As my prior post seemed "weird" to you, my goal was certainly not to confuse you, but I will take your stated opinion into consideration. GLTA. especially to the potential recipients of the MSTX pipeline. Do the DD if interested in MSTX.
